This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carr, J. A.
Right arrow Articles by Booth, R. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carr, J. A.
Right arrow Articles by Booth, R. F.

 Previous Article  |  Next Article 

J. Virol., 10 1997, 7799-7803, Vol 71, No. 10
Copyright © 1997, American Society for Microbiology

Interleukin-12 exhibits potent antiviral activity in experimental herpesvirus infections

JA Carr, J Rogerson, MJ Mulqueen, NA Roberts and RF Booth
Virology Department, Roche Development Welwyn, Welwyn Garden City, Hertfordshire, United Kingdom.

The prophylactic and therapeutic efficacy of interleukin-12 was studied by using murine models of herpes simplex virus infection. Prophylactic administration consisted of two intraperitoneal doses of interleukin-12 given 48 and 24 h prior to infection. Therapeutic intraperitoneal administration of interleukin-12 commenced 6 h after the mice were infected with herpes simplex virus and was continued daily for a total of 5 days. Interleukin-12 therapy improved the survival rates of mice with systemic herpes simplex virus infection compared with those of placebo-treated infected mice. Subcutaneous administration of interleukin-12 also improved the rate of survival of mice after systemic herpes simplex virus infection, although higher doses were required to give comparable effects. Combined prophylactic and therapeutic administration of interleukin-12 produced the greatest effect on survival after an otherwise lethal systemic infection. Intraperitoneal administration of interleukin-12 for 2 days before and 3 days after systemic infection with herpes simplex virus resulted in survival of 80% of the mice. These surviving mice were resistant to subsequent reinfection with herpes simplex virus. Such resistance was apparently specific for herpes simplex virus infection, since a second group of survivors succumbed to a lethal infection with murine cytomegalovirus. Infectious virus was recovered from lumbar ganglia explants dissected from survivors of prophylactic interleukin-12 therapy and cultured for 5 days in vitro, suggesting that interleukin- 12 treatment did not prevent the establishment of latent herpes simplex virus infection. One action of interleukin-12 may be to enhance natural killer cell-mediated clearance of the virus. However, interleukin-12 therapy was also effective in mice carrying the beige mutation, which reduces natural killer cell lytic activity, suggesting that interleukin- 12 has additional activities in vivo.


This article has been cited by other articles:

  • Friebe, A., Siegling, A., Friederichs, S., Volk, H.-D., Weber, O. (2004). Immunomodulatory Effects of Inactivated Parapoxvirus Ovis (Orf Virus) on Human Peripheral Immune Cells: Induction of Cytokine Secretion in Monocytes and Th1-Like Cells. J. Virol. 78: 9400-9411 [Abstract] [Full Text]  
  • Rudolf, M. P., Fausch, S. C., Da Silva, D. M., Kast, W. M. (2001). Human Dendritic Cells Are Activated by Chimeric Human Papillomavirus Type-16 Virus-Like Particles and Induce Epitope-Specific Human T Cell Responses In Vitro. J. Immunol. 166: 5917-5924 [Abstract] [Full Text]  
  • Malmgaard, L., Paludan, S. R., Mogensen, S. C., Ellermann-Eriksen, S. (2000). Herpes simplex virus type 2 induces secretion of IL-12 by macrophages through a mechanism involving NF-{kappa}B. J. Gen. Virol. 81: 3011-3020 [Abstract] [Full Text]  
  • Maloy, K. J., Burkhart, C., Junt, T. M., Odermatt, B., Oxenius, A., Piali, L., Zinkernagel, R. M., Hengartner, H. (2000). Cd4+ T Cell Subsets during Virus Infection: Protective Capacity Depends on Effector Cytokine Secretion and on Migratory Capability. JEM 191: 2159-2170 [Abstract] [Full Text]  
  • Lukaszewski, R. A., Brooks, T. J. G. (2000). Pegylated Alpha Interferon Is an Effective Treatment for Virulent Venezuelan Equine Encephalitis Virus and Has Profound Effects on the Host Immune Response to Infection. J. Virol. 74: 5006-5015 [Abstract] [Full Text]  
  • Pien, G. C., Biron, C. A. (2000). Compartmental Differences in NK Cell Responsiveness to IL-12 During Lymphocytic Choriomeningitis Virus Infection. J. Immunol. 164: 994-1001 [Abstract] [Full Text]  
  • Gherardi, M. M., Ramirez, J. C., Rodriguez, D., Rodriguez, J. R., Sano, G.-I., Zavala, F., Esteban, M. (1999). IL-12 Delivery from Recombinant Vaccinia Virus Attenuates the Vector and Enhances the Cellular Immune Response Against HIV-1 Env in a Dose-Dependent Manner. J. Immunol. 162: 6724-6733 [Abstract] [Full Text]  
  • Sin, J.-I., Kim, J. J., Arnold, R. L., Shroff, K. E., McCallus, D., Pachuk, C., McElhiney, S. P., Wolf, M. W., Pompa-de Bruin, S. J., Higgins, T. J., Ciccarelli, R. B., Weiner, D. B. (1999). IL-12 Gene as a DNA Vaccine Adjuvant in a Herpes Mouse Model: IL-12 Enhances Th1-Type CD4+ T Cell-Mediated Protective Immunity Against Herpes Simplex Virus-2 Challenge. J. Immunol. 162: 2912-2921 [Abstract] [Full Text]  
  • Sin, J.-I., Kim, J. J., Boyer, J. D., Ciccarelli, R. B., Higgins, T. J., Weiner, D. B. (1999). In Vivo Modulation of Vaccine-Induced Immune Responses toward a Th1 Phenotype Increases Potency and Vaccine Effectiveness in a Herpes Simplex Virus Type 2 Mouse Model. J. Virol. 73: 501-509 [Abstract] [Full Text]  
  • Parker, J. N., Gillespie, G. Y., Love, C. E., Randall, S., Whitley, R. J., Markert, J. M. (2000). From the Cover: Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc. Natl. Acad. Sci. USA 97: 2208-2213 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»